Code
MOG-RAFX-03BZ
Profile
Active-Compendium
Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive Myeloid Disorders, or one of the NeoTYPE Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2-3 mL in sodium heparin tube. EDTA is acceptable.<br>
<b>Peripheral Blood:</b> 5 mL in sodium heparin tube. EDTA is acceptable.<br>
<b>Fluids:</b> Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).</p>
<b>Peripheral Blood:</b> 5 mL in sodium heparin tube. EDTA is acceptable.<br>
<b>Fluids:</b> Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).</p>
Flag Active
True
Orderable Test Description
<p>The Rapid AML Therapeutic Panel was designed to assess key biomarkers associated with acute myeloid leukemia (AML). It includes the following testing methodologies and markers:<br><br>
Sanger Sequencing:<br>
TP53<br><br>
PCR/Fragment Analysis:<br>
FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA<br><br>
FISH Probes:<br>
5q-, -5 (5p15, 5q31, 5q33)<br>
7q-, -7 (Cen 7, 7q22, 7q31)<br>
RUNX1/RUNX1T1 (ETO/AML1) t(8;21)<br>
MLL (11q23)<br>
PML/RARA t(15;17)<br>
CBFB inv(16), t(16;16)<br>
17p- (TP53 17p13.1, NF1 17q11.2)<br><br>
Test reports include a summary of all results together.</p>
Sanger Sequencing:<br>
TP53<br><br>
PCR/Fragment Analysis:<br>
FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA<br><br>
FISH Probes:<br>
5q-, -5 (5p15, 5q31, 5q33)<br>
7q-, -7 (Cen 7, 7q22, 7q31)<br>
RUNX1/RUNX1T1 (ETO/AML1) t(8;21)<br>
MLL (11q23)<br>
PML/RARA t(15;17)<br>
CBFB inv(16), t(16;16)<br>
17p- (TP53 17p13.1, NF1 17q11.2)<br><br>
Test reports include a summary of all results together.</p>
Orderable Turn Around Time
10 Days
Orderable Biomarkers
NY Approved
False
Orderable Biomarkers JSON
{"Fluorescence In Situ Hybridization (FISH)": {"Translocation(s)": ["RUNX1T1/RUNX1 (ETO/AML1) t(8;21)", "PML/RARA t(15;17)"], "Deletion(s)": ["17p-", "5q-", "7q-"], "CNVs": ["CBFB"], "Rearrangement(s)": ["MLL"]}, "DNA Sequencing": {"SNVs + Indels": ["IDH1", "IDH2", "NPM1", "FLT3", "TP53", "CEBPA"]}}
Keywords string
AML, acute myeloid leukemia, risk stratification, client-bill Rapid AML Therapeutic Panel
Title URL
rapid-aml-therapeutic-panel
Clinical Significance
The Rapid AML Therapeutic Panel identifies genetic abnormalities associated with Acute Myeloid Leukemia (AML) that are useful for risk stratification and therapeutic decision making. This panel utilizes a combination of bi-directional Sanger sequencing, PCR and FISH with a fast turnaround time. AML is usually an in-patient hematologic diagnosis and prompt time to treatment assignment can improve patient outcomes significantly.
TAT Details
FISH: 5 Days
FLT3, IDH1, IDH2: 5 Days
CEBPA, NPM1, TP53: 7-10 Days
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.